300
Participants
Start Date
March 16, 2023
Primary Completion Date
May 19, 2027
Study Completion Date
March 17, 2031
Nemtabrutinib
65 mg administered orally daily until disease progression, unacceptable toxicity, or discontinuation criteria met.
Fludarabine
25 mg/m\^2 administered via intravenous (IV) infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
Cyclophosphamide
250 mg/m\^2 administered via IV infusion on Days 1, 2, and 3 of each 28-day cycle up to 6 cycles.
Bendamustine
Administered via IV infusion on Days 1 and 2 of each 28-day cycle up to 6 cycles. The first dose is given as 70 to 90 mg/m\^2. Subsequent doses may be escalated up to 90 mg/m\^2, if applicable and as per local guidelines.
Rituximab
Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Truxima
Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Ruxience
Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
Riabni
Administered as an IV infusion on Day 1 of each 28-day cycle. The initial dose is 375 mg/m\^2 (cycle 1) followed by 500 mg/m\^2 for remaining cycles.
National Cheng Kung University Hospital ( Site 4701), Tainan City
Specialized Hospital for Active Treatment of Haematology Diseases ( Site 6403), Sofia
Wits Clinical Research ( Site 4403), Johannesburg
"Multriprofile Hospital for Active Treatment Hristo Botev ( Site 6402)", Vratsa
Heves Vármegyei Markhot Ferenc Oktatókórház és Rendelőintézet ( Site 2608), Eger
"University Multiprofile Hospital for Active Treatment Sveti Georgi EAD ( Site 6404)", Plovdiv
Medical Centre Pratia Clinic EOOD ( Site 6406), Plovdiv
Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór-Haematológia osztály ( Site 2602), Nyíregyháza
Royal Adelaide Hospital ( Site 1105), Adelaide
Odense Universitetshospital ( Site 1900), Odense C
"UMHAT Prof. Dr. Stoyan KirkovichAD-Clinical Hematology ( Site 6400)", Stara Zagora
Vejle Sygehus ( Site 1903), Vejle
Haemalife ( Site 4407), Kuilsriver
Constantiaberg Haematology ( Site 4408), Plumstead
Groote Schuur Hospital-Clinical Haematology ( Site 4400), Cape Town
Fejér Megyei Szent György Egyetemi Oktató Kórház ( Site 2609), Székesfehérvár
Aarhus Universitetshospital, Skejby-Blodsygdomme ( Site 1902), Aarhus
Aalborg Universitetshospital, Syd ( Site 1901), Aalborg
National Taiwan University Hospital ( Site 4704), Taipei
MNPE ClinCenter of Oncology,Hematology,Transplantology and Palliative Care of CherkasyRegCouncil ( Site 5106), Cherkassy
Mega Medipol-Hematology ( Site 4904), Stanbul
Clermont Oncology Center ( Site 5224), Clermont
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 4906), Istanbul
Ege Universitesi Hastanesi ( Site 4902), Izmir
Hattiesburg Clinic Hematology/Oncology ( Site 5216), Hattiesburg
Hospital of Lithuanian University of Health Sciences Kauno klinikos-Oncology and Hematology ( Site 3100), Kaunas
Centro de Investigacion Clinica Chapultepec ( Site 3309), Morelia
Namik Kemal University Medical Faculty-Hematology ( Site 4912), Suleymanpasa
Hospital Ampang ( Site 3202), Ampang
Oaxaca Site Management Organization ( Site 3313), Oaxaca City
Highlands Oncology Group ( Site 5205), Springdale
"Communal non-profit enterprise Regional clinical hospital o-Hematology Department ( Site 5113)", Ivano-Frankivsk
Institute of Blood Pathology and Transfusion Medicine of National Aсademy of Medical Sciences of Ukr ( Site 5105), Lviv
Hospital Sultanah Aminah ( Site 3203), Johor Bahru
Chang Gung Memorial Hospital at Kaohsiung-Division of Hematology and Oncology ( Site 4700), Kaohsiung City
Medical Oncology Associates, PS ( Site 5206), Spokane
Peking University Third Hospital ( Site 1602), Beijing
The First Hospital of Jilin University-Hematology ( Site 1621), Changchun
National Cancer Centre Singapore ( Site 4200), Singapore
Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1704), Valledupar
Fudan University Shanghai Cancer Center ( Site 1606), Shanghai
The First Affiliated Hospital of Soochow University-hematology department ( Site 1612), Suzhou
Institute of hematology&blood disease hospital ( Site 1600), Tianjin
Tianjin Medical University Cancer Institute & Hospital-lymphoma ( Site 1604), Tianjin
Tan Tock Seng Hospital ( Site 4202), Singapore
The First Affiliated Hospital, Zhejiang University-Hematology ( Site 1611), Hangzhou
The First Affiliated Hospital of Nanchang University ( Site 1614), Nanchang
Jiangxi Provincial Cancer Hospital ( Site 1628), Nanchang
Institutul Oncologic Cluj ( Site 4002), Cluj-Napoca
Chongqing University Cancer Hospital ( Site 1605), Chongqing
Chongqing University Three Gorges Hospital ( Site 1609), Chongqing
Xiangya Hospital Central South University-Hematology department ( Site 1616), Changsha
Hunan Cancer Hospital ( Site 1615), Changsha
Tongji Hospital Tongji Medical,Science & Technology ( Site 1619), Wuhan
Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1618), Wuhan
Henan Cancer Hospital-hematology department ( Site 1613), Zhengzhou
Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 1607), Guangzhou
Sun Yat-sen University Cancer Center ( Site 1608), Guangzhou
The Affiliated Hospital of Guizhou Medical University ( Site 1625), Guiyang
Hainan General Hospital ( Site 1603), Haikou
Oncologos del Occidente ( Site 1706), Pereira
The First Affiliated Hospital of Xi'an Jiaotong University ( Site 1617), Xi'an
Shaanxi provincial people's hospital ( Site 1626), Xi'an
IC La Serena Research ( Site 1506), La Serena
Biocenter ( Site 1507), Concepción
James Lind Centro de Investigacion del Cancer ( Site 1503), Temuco
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509), Santiago
FALP-UIDO ( Site 1500), Santiago
Clínica Inmunocel ( Site 1511), Santiago
Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1317), Curitiba
Hospital Amaral Carvalho-Centro de Pesquisas ( Site 1304), Jaú
A. C. Camargo Cancer Center ( Site 1318), São Paulo
Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1319), Rio de Janeiro
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308), São Paulo
Hospital Paulistano-Americas Oncologia ( Site 1302), São Paulo
Shanxi Cancer Hospital ( Site 1629), Taiyuan
Clini Salud ( Site 1700), Envigado
Fundacion Colombiana de Cancerología Clinica Vida ( Site 1707), Medellín
MEDI-K ( Site 2401), Guatemala City
CELAN,S.A ( Site 2403), Guatemala City
Oncomedica ( Site 2402), Guatemala City
Queen Mary Hospital ( Site 2500), Hksar
Centro de Infusion Superare ( Site 3314), Mexico City
Health Pharma Professional Research S.A. de C.V: ( Site 3301), Mexico City
Uniwersytecki Szpital Kliniczny nr 1 w Lublinie ( Site 3710), Lublin
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 3701), Warsaw
Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 3702), Gdansk
Pratia Onkologia Katowice ( Site 3705), Katowice
Samodzielny Publiczny Zaklad Opieki Zdrowotnej MSWiA z Warmi-Oddzial Kliniczny Hematologii ( Site 3704), Olsztyn
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S ( Site 3711), Kielce
Spitalul Clinic Colțea ( Site 4000), Bucharest
Spitalul Clinic Colțea ( Site 4001), Bucharest
Netcare Pretoria East Hospital-Albert Alberts Stem Cell Transplant Centre ( Site 4401), Centurion
Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 4913), Ankara
Nonprofit Organization National Cancer Institute ( Site 5103), Kyiv
SI National Research Center of Radiation Medicine, Hematology, Oncology ( Site 5101), Kyiv
Public Non-Profit Enterprise Kyiv City Clinical Hospital #9 -Hematology department #1 ( Site 5111), Kyiv
Merck Sharp & Dohme LLC
INDUSTRY